HOWL (NASDAQ) - Werewolf Therapeutics Inc

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. Web URL:

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for HOWL (NASDAQ) - Werewolf Therapeutics Inc


Market Cap in USD 93m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2021-04-30


Fundamental -0.49
Dividend -
Performance 5y -5.92
Rel. Performance vs Sector -0.32
Analysts 4.80
Fair Price Total Ret. 1.50
Fair Price DCF todo


Growth TTM -61.89%
CAGR 5y -58.00%
CAGR / Mean Drawdown 5y -0.92
Sharpe Ratio TTM -0.66
Alpha vs SP500 TTM -82.64
Beta vs SP500 5y weekly 1.07
CAPM 7.66%
Average Daily Range 2m 7.96%
Reversal Oscillator 8.21
Volatility GJR Garch 1y 104.91%
Price / SMA 50 -25.74%
Price / SMA 200 -27.08%
Current Volume 38.3k
Average Volume 20d 21.4k


Yield TTM 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Consistency of Dividends all time 0.0%